Abstract:Background: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic options of hepatobiliary malignancies. However, the clinical benefit provided by immunotherapy seems limited to a small subgroup of patients with hepatobiliary malignancies. The identification of reliable predictors of the response to immunotherapy is urgently needed. Data sources: Literature search was conducted in PubMed for relevant articles published up to May 2022. Information of clinical trials was obtained from https://clinicaltrials.gov/. Results: Biomarkers for ICI response of hepatobiliary malignancies remain in the exploration stage and lack compelling evidence. Tumor programmed death-ligand 1 (PD-L1) expression is the most widely studied biomarker in hepatocellular carcinoma (HCC) and biliary tract cancers (BTCs), but there are conflicting results on its predictive potential. Tumor mutational burden (TMB) is generally low both in HCC and BTCs, and the clinical trials of TMB are rare in hepatobiliary malignancies. Promisingly, mismatch repair deficiency (dMMR)/high microsatellite instability (MSI-H) may be a predictive biomarker of response to anti-PD-1 therapy in BTCs. Furthermore, some emerging biomarkers, such as gut microbiota, show predictive potential in the preliminary studies. Radiomics and liquid-biopsy biomarkers, including circulating tumor cells, circulating tumor DNA (ctDNA) and exosomal PD-L1 provide a quick and non-invasive approach for monitoring the ICI response, showing a new promising direction. Conclusions: Multiple potential biomarkers for predicting ICI response of hepatobiliary malignancies have been explored and tried to apply in clinic. Yet there is no robust evidence to prove their clinical value in predicting immunotherapeutic response for patients with hepatobiliary malignancies. The identification of predictors for response to ICIs is an urgent need and major challenge. Further studies are warranted to validate the role of emerging biomarkers in predicting immunotherapeutic responses.

The development of biomarkers for cancer immunotherapy

Progresses in biomarkers for cancer immunotherapy

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Biomarkers for response to immunotherapy in hepatobiliary malignancies

Research progress in dynamic monitoring of lung cancer immunotherapy

Advances and prospects of biomarkers for immune checkpoint inhibitors

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Predictive Biomarkers for Cancer Immunotherapy with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors: recent progress and potential biomarkers

Predictive biomarkers for checkpoint blockade-based immunotherapy

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade

Mechanistic Insight of Predictive Biomarkers for Antitumor PD‑1/PD‑L1 Blockade: A Paradigm Shift Towards Immunome Evaluation (Review)

The advances in immunotherapy biomarkers of small cell lung cancer

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers

Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

[Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer].

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

The Key to Immunotherapy: How to Choose Better Therapeutic Biomarkers for Patients with Non-Small Cell Lung Cancer.